Prolactinoma: What to Do When Standard Dopamine Agonist Therapy Fails

In some patients with prolactinoma, first-line treatment with a dopamine agonist does not achieve the expected response. This protocol addresses the clinical step taken when that failure is confirmed.

Previous Treatment — Goals Not Reached

First-line therapy with a dopamine agonist — primarily cabergoline, or bromocriptine as an alternative — at standard doses failed to achieve prolactin normalisation, at least 50% reduction in tumour size, and restoration of gonadal function.

Next-Line Approach — Partial Overview

The next step centres on escalation of cabergoline to the maximally tolerated dose to overcome resistance — the complete dosing strategy, decision algorithm, and full protocol remain available via the structured regimen.

Treatment Goals

Prolactin normalisation and at least 50% reduction in tumour size.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1210/clinem/dgad174

In patients resistant to a certain DA, dose escalation to maximally tolerated doses is recommended, as in clinical case 3.

Cabergoline doses as high as 12 mg/wk have been needed to overthrow resistance.

According to international guidelines (34), resistance to DA occurs in case of failure to achieve PRL normalization and at least ≥50% reduction in tumor size at maximally tolerated doses.

View source ↗